Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Commercialisation of a novel drug discovery target critical for the development of autoimmune diseases

Reference number
Coordinator IMMUNSCAPE AB
Funding from Vinnova SEK 300 000
Project duration November 2017 - April 2018
Status Completed
Venture Innovative Startups

Purpose and goal

In this project the intention was to develop an academic project into a commercially viable drug discovery project. The project validated one chemical series with submicromolar affinity by developing a new assay and identified a second series via a different mechanism of action. Furthermore, we were able to show that both series have good properties to be developed into drugs and are patentable. These compounds can now be used in proof-of-concept studies to validate the target in vivo.

Expected effects and result

The supported project accelerated the scientific validation of a new target for the treatment of autoimmune diseases that will be critical to attract further funding. Within a year we expect to have a lead candidate with a validated effect in animal models. This will be critical in the discussion with big pharma companies to ensure the progress and funding of the project

Planned approach and implementation

Combining in vivo and project expertise with researchers at Karolinska Institutet with drug development expertise in Immunscape has proved beneficial for the project. The new method developed during the project enabled the validation of target inhibiting molecules. Furthermore, the evaluation and application of an alternative mechanism of action gave a new attractive therapeutic direction of the project with the possibility of faster market entry.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 May 2019

Reference number 2017-04057

Page statistics